Last updated: September 3, 2026
Polymyxin B sulfate and trimethoprim sulfate ophthalmic solution is a mature topical antibiotic combination marketed primarily as Polytrim and generic equivalents. Its commercial profile is defined by low-cost generic competition, limited patent protection, stable outpatient demand, and modest revenue per prescription. The product has no biosimilar pathway, no meaningful remaining small-molecule exclusivity barrier, and limited capacity for premium pricing.
What is polymyxin B sulfate and trimethoprim sulfate?
Polymyxin B sulfate and trimethoprim sulfate is an ophthalmic antibacterial combination used for susceptible bacterial infections of the eye and surrounding structures. The standard formulation contains:
| Component |
Typical concentration |
Function |
| Polymyxin B sulfate |
10,000 units/mL |
Disrupts bacterial cell membranes |
| Trimethoprim sulfate |
1 mg/mL |
Inhibits bacterial dihydrofolate reductase |
| Dosage form |
Sterile ophthalmic solution |
Topical ocular delivery |
The product is indicated for conditions such as bacterial conjunctivitis and blepharoconjunctivitis when caused by susceptible organisms. It is not an antiviral, antifungal, or anti-inflammatory product. The FDA-approved label identifies the combination as a topical antibacterial prescription medicine.[1]
The combination has commercial value because it provides two antibacterial mechanisms in a low-cost liquid formulation. Its clinical use is concentrated in primary care, pediatrics, ophthalmology, urgent care, and retail prescribing.
What is the FDA regulatory status of Polytrim?
Polytrim was approved by the FDA as a new drug application product, identified as NDA 050545 in FDA product information.[2] The product is a prescription ophthalmic solution.
The principal regulatory characteristics are:
| Regulatory attribute |
Status |
| Active ingredients |
Polymyxin B sulfate and trimethoprim sulfate |
| Route |
Ophthalmic |
| Product type |
Small-molecule combination drug |
| FDA pathway |
Original NDA, followed by generic ANDA competition |
| Prescription status |
Prescription |
| Biosimilar eligibility |
Not applicable |
| Pediatric use |
Label-supported use in children, subject to prescribing information |
| Current commercial structure |
Brand and multiple generic products |
Because this is a small-molecule topical combination, competitors generally enter through abbreviated new drug applications rather than the biosimilar pathway. FDA-approved generics must demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable ANDA requirements.[3]
When does polymyxin B and trimethoprim lose exclusivity?
The product lost practical market exclusivity years ago. Any original composition, formulation, or regulatory exclusivity associated with the 1980s-era NDA no longer prevents generic entry.
A relevant exclusivity timeline is:
| Event |
Approximate timing |
Commercial effect |
| Original FDA approval |
1980s |
Initial branded market |
| Generic ANDA development |
Subsequent decades |
Entry under abbreviated pathway |
| Patent and regulatory exclusivity expiry |
Long expired |
Removal of meaningful legal barriers |
| Current market |
Mature generic stage |
Price and supply competition |
The exact expiration of any original patent is less important than the present market structure. The product has been commercially genericized for many years, and no widely recognized active patent estate appears to protect the core combination or its conventional ophthalmic solution.
What patents protect polymyxin B sulfate and trimethoprim sulfate?
The core drug combination has weak current patent protection. Publicly available FDA product information identifies the active ingredients and approved formulation, but the commercial product is not generally associated with an active Orange Book patent blocking generic competition.[1,2]
Core composition patents
The combination uses established antibacterial agents rather than a recently discovered chemical entity. Polymyxin B sulfate is an established antibiotic mixture, while trimethoprim sulfate is a long-established antibacterial active ingredient. The product’s value comes from combining known actives in an ophthalmic solution.
The practical patent position is therefore:
| Patent category |
Current protection assessment |
| New chemical entity patent |
Not commercially relevant |
| Core combination patent |
Expired or not a current market barrier |
| Ophthalmic solution patent |
No widely recognized active blocking patent |
| Method-of-use patent |
No material exclusivity identified for routine labeled use |
| Manufacturing patent |
Potentially applicable to individual suppliers, but not a market-wide barrier |
| Device or delivery patent |
Limited relevance to the standard dropper bottle |
| Orange Book-listed blocking patents |
No material current barrier generally relied on for entry |
Manufacturing know-how can still matter operationally. Sterility assurance, preservative control, container-closure integrity, particle control, and stability testing create technical requirements. Those requirements are quality and execution barriers rather than durable exclusivity rights.
Formulation patents
The standard product is a sterile aqueous ophthalmic solution. Its formulation is comparatively straightforward relative to emulsions, suspensions, depot systems, lipid nanoparticles, or preservative-free multidose delivery systems.
Potential formulation differentiation can involve:
- Preservative concentration
- pH and tonicity
- Container-closure system
- Drop size
- Stability profile
- Preservative-free packaging
- Multidose delivery technology
These features could support separate intellectual property in a redesigned product, but they do not generally protect the conventional polymyxin B and trimethoprim ophthalmic solution from generic competition.
What is the Orange Book status of Polytrim?
The Orange Book is relevant because it identifies FDA-approved prescription products and certain patent and exclusivity information. Polytrim’s commercial position is consistent with an old NDA product facing generic competition rather than a product protected by current listed patents.
The practical Orange Book implications are:
- The NDA establishes the reference product for generic development.
- Generic applicants can pursue ANDA approval.
- Paragraph IV litigation is unlikely to be a material current issue because the principal product exclusivity period has elapsed.
- The commercial market is driven by generic approvals, supply reliability, reimbursement, and contracting.
The absence of a meaningful current patent barrier does not eliminate all regulatory disputes. Applicants can still face FDA review issues involving labeling, manufacturing sites, facility inspections, bioequivalence documentation, or product quality.
Which companies compete in the polymyxin B and trimethoprim market?
Competition comes from the original brand owner, generic ophthalmic manufacturers, contract manufacturers, wholesalers, and pharmacy suppliers. The precise supplier roster can change as FDA approvals are transferred, discontinued, or supplied through private-label arrangements.
The competitive field includes:
- The Polytrim branded product
- FDA-approved generic polymyxin B sulfate and trimethoprim sulfate ophthalmic solutions
- Retail pharmacy generic labels
- Hospital and clinic purchasing contracts
- Alternative ophthalmic antibiotic products
Direct competitors include trimethoprim sulfate ophthalmic solution, tobramycin ophthalmic products, fluoroquinolone ophthalmic products, and erythromycin ophthalmic ointment. Prescribers select among these options based on suspected pathogens, age, allergy history, local resistance, formulation preference, price, and formulary position.
How does polymyxin B and trimethoprim compare with competing ophthalmic antibiotics?
| Product class |
Common examples |
Main commercial advantage |
Main limitation |
| Polymyxin B plus trimethoprim |
Polytrim and generics |
Low cost and dual mechanism |
Limited coverage for some resistant organisms |
| Fluoroquinolones |
Ofloxacin, ciprofloxacin, moxifloxacin |
Broad antibacterial coverage |
Higher price in some channels and stewardship concerns |
| Aminoglycosides |
Tobramycin, gentamicin |
Familiar topical therapy |
Potential toxicity and narrower tolerability profile |
| Macrolides |
Erythromycin ointment |
Useful ointment formulation and pediatric familiarity |
Lower convenience and resistance limitations |
| Combination steroid-antibiotics |
Various products |
Addresses inflammation with infection |
Steroid-related risks and more complex prescribing |
Polymyxin B and trimethoprim is positioned as a value product. It competes effectively where a low-cost, broad-enough topical antibacterial is clinically acceptable. It is less advantaged when physicians prefer fluoroquinolones for broader coverage, when a patient needs an ointment, or when resistance patterns make the combination less suitable.
What are the main market dynamics?
Generic price erosion
The largest market force is generic substitution. Once multiple suppliers are available, pharmacy benefit managers, wholesalers, and health systems can negotiate lower prices. The brand may retain demand through prescriber familiarity, supply availability, or contractual positioning, but it generally faces a substantial volume and price disadvantage.
Stable but non-growth demand
Demand is linked to the incidence of bacterial eye infections and prescribing behavior. It is not strongly linked to chronic disease prevalence because treatment courses are usually short. Volume can vary seasonally and with pediatric infection trends, but the market does not have the recurring revenue profile of chronic ophthalmology products.
Low switching costs
Patients and prescribers can switch between generic suppliers without changing the active ingredients or therapeutic concept. Pharmacies may substitute among therapeutically equivalent products when permitted by state law and payer rules.
Supply-chain sensitivity
The product is relatively inexpensive, which limits the economic incentive for manufacturers to maintain excess capacity. Shortages can occur if a supplier experiences:
- Sterility failures
- Manufacturing-site delays
- Active ingredient constraints
- Container shortages
- FDA compliance problems
- Low-margin portfolio rationalization
A supply disruption can temporarily increase branded or alternate-generic demand, but it does not usually create durable pricing power.
Stewardship pressure
Antibiotic stewardship can reduce unnecessary prescribing, particularly for viral conjunctivitis. That pressure may constrain total prescription volume but can improve prescribing quality by directing use toward patients with suspected bacterial disease.
What is the financial trajectory for polymyxin B and trimethoprim?
The financial trajectory is mature, defensive, and low growth.
| Financial phase |
Revenue pattern |
Margin profile |
| Branded launch |
Growth from adoption and formulary access |
Higher branded margins |
| Early generic entry |
Volume migration and price compression |
Margin decline |
| Mature generic market |
Stable unit demand with low average selling price |
Thin to moderate supplier margins |
| Supply disruption periods |
Temporary price and share volatility |
Potential short-term margin expansion |
| Long-term outlook |
Flat to modest decline in nominal revenue |
Cost and supply execution determine profitability |
Standalone revenue for the active-ingredient combination is generally not reported by public companies because it is included within broader ophthalmology, generic, or prescription-product portfolios. The commercial value is therefore better assessed through prescription volume, average selling price, supplier share, gross margin, and shortage exposure than through a separately disclosed product revenue line.
Revenue exposure by commercial model
Brand owner
The brand owner faces:
- Generic substitution
- Lower net prices
- Reduced formulary leverage
- Promotional constraints
- Dependence on brand recognition and availability
Brand revenue can remain viable if the product maintains a meaningful cash-pay, pediatric, or prescriber-loyalty segment. It is unlikely to produce high growth without a reformulation, new delivery system, or expanded indication.
Generic manufacturer
Generic suppliers compete on:
- Manufacturing cost
- FDA compliance
- Supply reliability
- Wholesale contracts
- Pharmacy distribution
- Ability to remain active during competitor shortages
Generic economics can be attractive when the number of approved suppliers is limited. They deteriorate when several suppliers compete for the same retail and institutional contracts.
Distributor and pharmacy
Distributors and pharmacies typically earn through purchasing spreads, dispensing fees, and reimbursement arrangements. The product’s low unit price limits absolute dollar profit per prescription, making volume and supply continuity important.
Are there Paragraph IV challenges or patent litigation?
No major current Paragraph IV or patent-litigation issue is central to the mature market for polymyxin B sulfate and trimethoprim sulfate ophthalmic solution.
Paragraph IV litigation is most commercially important when an ANDA applicant challenges an unexpired Orange Book patent. The core product does not appear to depend on an active patent blocking generic entry. Any historical patent dispute would have limited relevance to current market access unless it produced a continuing settlement restriction, which is not a recognized feature of the present market.
Potential disputes are more likely to involve:
- Generic product quality
- Manufacturing compliance
- False or misleading promotion
- Labeling
- Distribution contracts
- Pharmacy substitution
- Shortage allocation
- Product liability
What generic launch scenarios exist?
Base case: continued generic erosion
The most likely scenario is stable generic availability with gradual price pressure. Brand share remains limited, while generic products capture most prescription volume.
Upside case: supplier consolidation or shortage
A manufacturing disruption or supplier exit could tighten supply. Remaining manufacturers could gain volume and temporarily improve pricing. The effect would depend on duration and the number of approved alternatives.
Downside case: demand substitution
Prescribers may shift toward fluoroquinolones, alternative antibiotics, or observation without antibiotics. This would reduce volume, especially if clinical guidelines and stewardship programs discourage routine antibiotic treatment for uncomplicated conjunctivitis.
Product-renewal case
A reformulated product could create new commercial value through preservative-free packaging, improved delivery, longer stability, or a differentiated pediatric presentation. That strategy would require new clinical, regulatory, manufacturing, and intellectual-property investment. The existing combination alone does not support premium-growth economics.
What manufacturing and IP barriers affect the market?
The principal barriers are operational rather than patent-based. Manufacturers must produce a sterile ophthalmic product with consistent potency, acceptable impurities, reliable container closure, and validated microbiological control.
Important technical risks include:
- Sterility assurance
- Preservative effectiveness
- Extractables and leachables
- Particulate matter
- Drop uniformity
- Stability after opening
- Active ingredient compatibility
- Packaging integrity
- FDA inspection findings
Polymyxin B is a complex antibiotic mixture rather than a single simple synthetic molecule. Control of potency and composition can create analytical and quality challenges. Trimethoprim sulfate is more chemically defined, but the finished combination still requires control of the complete ophthalmic formulation.
These barriers may reduce the number of reliable suppliers. They do not create the same durable exclusion as a valid, enforceable patent.
How strong is the patent estate for polymyxin B and trimethoprim?
The patent estate is weak for the conventional product. Its commercial defensibility depends on brand recognition, supplier reliability, manufacturing quality, distribution access, and temporary market shortages.
| Asset |
Strength |
| Core active ingredients |
Very weak exclusivity position |
| Conventional combination |
Weak |
| Standard ophthalmic solution |
Weak |
| Manufacturing know-how |
Moderate operational value |
| Brand recognition |
Moderate but declining under generic substitution |
| Supply reliability |
Potentially valuable |
| New delivery technology |
Could be strong if separately patented and clinically differentiated |
Key Takeaways
- Polymyxin B sulfate and trimethoprim sulfate is a mature prescription ophthalmic antibacterial combination.
- Polytrim is the reference branded product, while generic versions determine most market economics.
- Core patent and regulatory exclusivity have expired or no longer function as meaningful market barriers.
- No biosimilar risk applies because the product is a small-molecule combination drug.
- Current competition centers on generic price, supply continuity, FDA compliance, and pharmacy access.
- Standalone product revenue is generally not disclosed by manufacturers.
- Financial performance is likely stable to declining in normal conditions, with temporary upside during supply disruptions.
- The strongest remaining commercial assets are manufacturing capability, reliable supply, distribution, and any genuinely differentiated delivery technology.
- Paragraph IV litigation is not a central current risk for the conventional product.
- A branded growth strategy would require reformulation, new packaging, expanded clinical positioning, or a separate delivery-system patent estate.
FAQs
Is Polytrim still patent protected?
The conventional Polytrim combination is not generally viewed as protected by an active patent that prevents generic entry. Generic competition has been established for many years.
Is polymyxin B and trimethoprim available over the counter?
The standard ophthalmic combination is marketed as a prescription product in the United States. It is not an ordinary over-the-counter eye drop.
Does polymyxin B and trimethoprim have biosimilar competition?
No. Biosimilars apply to biologic products. This combination is a small-molecule ophthalmic drug and competes through generic ANDA products.
Can a new preservative-free version obtain patent protection?
Potentially. A preservative-free formulation, specialized container, controlled-drop delivery system, or other novel product configuration could support separate patent claims if it satisfies patentability and regulatory requirements.
What would increase the product’s commercial value?
The strongest potential drivers are sustained generic shortages, supplier consolidation, improved manufacturing reliability, a differentiated preservative-free presentation, and new delivery technology that supports premium reimbursement.
References
-
U.S. Food and Drug Administration. (n.d.). Polytrim: Polymyxin B sulfate and trimethoprim sulfate ophthalmic solution prescribing information. FDA labeling database.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Polytrim, NDA 050545. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations
-
National Library of Medicine. (n.d.). DailyMed: Polymyxin B sulfate and trimethoprim sulfate ophthalmic solution. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations and abbreviated new drug application guidance. https://www.fda.gov/drugs/guidance-compliance-regulatory-information-drugs---
